Project Details
Description
Weeks 1-6: Novel drug and combination drug screening will be performed on inflamed synovial cells in vitro (MH7A synovial fibroblasts). Synovial cells will be inflamed with lipopolysaccharide (LPS) insult to mimic in vitro conditions of RA and cultured in DMEM and fetal bovine serum at 37 °C and 5% CO2. Subsequent experiments will be performed when cells are microscopically observed to reach 80-90% confluency. Inflamed synovial cells will be treated with drugs from the finite list of robust sensitizing drugs at different doses at regular time intervals. After treatment, cells will be seeded into 96-well plates at density of 8000 cells/wells. Trypan blue stain and heamocytometer will be used along with RealTimeGlo reagent to determine the post-treatment cell quantity and viability. Total RNA will be extracted from cells using TRIzol reagent as per manufacturer’s protocols. cDNA will be synthesised from RNA using a PrimeScript RT Reagent Kit as per manufacturer’s instructions. PCR to determine the post-treatment gene expression of GAPDH, ACOX3, ZNF688 and ZBTB40 will be conducted using an amplification procedure including initial denaturation at 94°C for 5 min, 40 cycles of 94°C for 5 s and 62°C for 30 s.
Weeks 7-12: write up of paper abstract, introduction, methods, results, discussion and references and submission to Arthritis Research and Therapy or equivalent peer reviewed journal.
| Status | Finished |
|---|---|
| Effective start/end date | 1/06/24 → 31/10/24 |
Funding
- Northern Ireland Rheumatism Trust: £4,500.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.